Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose Linearity and Safety of BC Combo THDB0207 in Type 2 Diabetes
NCT05373212Phase 1Completed
- Sponsor
- Adocia
- Start
- May 2022
- Primary completion
- Jan 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin glargine and insulin lispro in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Adocia. Primary endpoints: Area Under the Curve of Total Insulin from 0 to last measurable concentration at 30 hours and Maximum Concentration of Total Insulin at 30 hours. Started May 2022; status: completed.
02
Drugs
insulin glargineinsulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05373212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05373212.